Fundraising FoxFrazier Life Sciences — 2019 Investments
3 investments dated 2019 · listed companies and verified rows first · show all
Arcutis is a biopharmaceutical company focused on dermatology, developing treatments for immune-mediated skin diseases such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis.
BiotechHealthtechMedical DevicesWestlake Village, US
Todd Franklin Watanabe(Executive Officer, Director)Alexander Asam(Director)Ricky Sun(Director)
BoardJonathan Silverstein(Director)
Board seatPatrick HeronDaniel Estes· per SEC Form D
Co-investorsBain Capital Life SciencesRA Capital
Passage Bio is a biotechnology company developing treatments for central nervous system (CNS) diseases, with a focus on neurodegenerative conditions.
BiotechHealthtechPhiladelphia, US
William Chou(Chief Executive Officer)Tadataka Yamada(Executive Officer, Director, Promoter)Stephen Squinto(Executive Officer, Director)in
BoardCarl Gordon(Director)inThomas Street Address 1 Woiwode(Director)
Board seatPatrick Heron· per SEC Form D
Co-investorsAccess BiotechnologyFrazier Healthcare PartnersLilly Asia VenturesNew Leaf Venture PartnersOrbiMedSphera Funds Management+2 more
Chimerix is a biopharmaceutical company developing therapies for rare diseases and cancers, with a focus on advancing treatments through biomarker-driven approaches and precision medicine.
BiotechHealthtechMedical DevicesDurham, US
Mike Sherman(Chief Executive Officer and President)W. Garrett Nichols(Chief Medical Officer)Michael A. Alrutz(Executive Officer)Randall Lanier(Chief Science Officer)Roy W. Ware(Chief Manufacturing and Technology Officer)Heather Knight-Trent(Vice President of Regulatory Affairs)
Co-investorsAisling CapitalAlta PartnersAsset Management CompanyCanaan PartnersPappas CapitalSanderling Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.